BSE filing, NSE: BANSISONS. Summary written from the filing by ALFA Finder's alert engine.
Bansisons Tea Industries Ltd: key numbers
- Share price
- ₹8.08
- Market cap
- ₹5.11 Cr
- Revenue (annual)
- ₹0.10 Cr
- Net profit (annual)
- ₹-5.37 Cr
- P/E (TTM)
- -0.9×Sector 26.2×
- Promoter holding
- 23.15%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bansisons Tea Industries Ltd
All →Novyra Pharmachem Board Meeting Date
Novyra Pharmachem will hold a board meeting on 2 November 2026 to consider unaudited Q2 results. Agenda items remain proposed until the meeting.
Novyra Pharmachem Other Announcement
Novyra Pharmachem Ltd filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.
Novyra Pharmachem Other Announcement
Novyra Pharmachem intimated BSE of a change in its official email ID under Reg 30. The update is purely administrative with no business or financial impact.
Bansisons Tea Industries Other Announcement
The company has officially changed its name from Bansisons Tea Industries Limited to Novyra Pharmachem Limited. This change reflects the company's expansion into the pharmaceutical sector.
Bansisons Tea Industries Q1 FY27 Results: Net Profit ₹0 Cr
Bansisons Tea Industries Ltd reported revenue from operations of ₹1.7 Cr and net profit of ₹0 Cr for Q1 FY27.
- Key figure
- Net profit ₹0 Cr
Bansisons Tea Industries Board Meeting Date
Novyra Pharmachem Limited has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.